🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In a recent blog, the International Myeloma Foundation’s Dr. Durie discusses why belonging to a #myeloma community is important, and why keeping abreast of the latest #multiplemyeloma developments is essential bit.ly/3EsODf2

Cytopenias After CAR T-Cell Therapy: A Common and Cumbersome Challenge #MedTwitter dailynews.ascopubs.org/do/cytopenias-…

I’m disappointed w/ this news. As a patient I saw many patients benefiting from this therapy when they were out of options. I realize it comes w/ side effects, but I believe pts have the right to decide the risk: benefit ratio they R willing 2 take #mmsm gsk.com/en-gb/media/pr…

Joshua Richter, MD, FACP I am glad that GSK is working with the FDA to design a compassionate use program for #myeloma patients out of options. For those that respond they can be long .

I enjoyed being on a panel with 3 other great myeloma advocates. We spoke on health disparities in the black community for patients living with Myeloma. everydayhealth.com/multiple-myelo…

Tecvayli + Talquetamab show 84% ORR in a Phase 1 study to be presented at #ASCO23 ASCO #mmsm biopharmadive.com/news/johnson-j… via BioPharma Dive

Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study. #mmsm #ASCO23 ⁦Memorial Sloan Kettering Cancer Center⁩ ⁦MSK Department of Medicine⁩ meetings.asco.org/abstracts-pres…

Looking to learn how to address dosing, scheduling, patient preparedness, & toxicities, when using antibody & #Immunotherapy tx options for pts with #MultipleMyeloma? Join Robert Z. Orlowski, Biran Noam & Ajay Nooka, MD, MPH on 6/3 at 6:30 PM CDT at #ASCO23 buff.ly/3MEu0Qp PeerView

Look forward to talks with amazing speaker line up at the International Myeloma Foundation African American Initiative Council meeting Joseph Mikhael Yelak Biru Dr. Jeffrey Zonder Craig Emmitt Cole Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Much work needed in this area to educate engage and enhance: M-power #mmsm

In 2023, our M-Power initiative achieved remarkable milestones, fostering diversity and equity in myeloma care. Together, we're shaping a future where every voice is heard and every patient receives the support they deserve. Joseph Mikhael 🌍💪 #MPower2023 #DiversityInHealthcare 🌟

The #myeloma miracle! Myeloma UK Robin Tuohy Myeloma Aust _MFA Myeloma Patients Europe Myeloma Aust _MFA @DrlaLandgren Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Robin Tuohy Jack Aiello Jim Omel Myeloma New Zealand Luciano J Costa Jack Aiello UAMS Myeloma Center Shaji Kumar @DrMiguelPerales James R. Berenson, MD Robert Z. Orlowski marivi mateos

Balm and Gilead conference with Craig Emmitt Cole speaking on #multiplemyeloma #CARTtherapy #bispecifics and #healthdisparities

March is #MultipleMyelomaMonth, and I'm excited to join hip-hop legend MC Lyte, Marsha Calloway💕💚💕, and @DrMHB1 on 3/6 to discuss our unique journeys with multiple myeloma and how we can help improve outcomes for patients. Register here: bit.ly/49GdJnl #JNJPartner

In this Oncology Nursing News article, Beth Faiman PhD discusses, "First relapse in multiple myeloma: the patient perspective." #mmsm 63% of those who relapsed had no new symptoms. Support and shared decision-making can help you navigate the road ahead. She advises to focus on